Healthy Adult Male Volunteers
8
0
0
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
8 treatments under study, led by 14cshr6390
Research Leaders
5 sponsors active, led by Jiangsu HengRui Medicine Co., Ltd.
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 7 completed trials
Clinical Trials (8)
Clinical Pharmacology Study of MT-3534 in Healthy Adult Male Volunteers
ADME Study of [14C]-Jaktinib in Healthy Male Subjects
ADME Study of [14C]- Rongliflozin in Healthy Male Subjects
ADME Study of [14C]- Larotinib in Healthy Male Subjects
Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR1459 in Healthy Adult Male Volunteers
Evaluation of Systemic Bioavailability and Effects on 24-Hour Plasma Cortisol Profile of 6 mg Delivered Once Daily Versus 3 mg Delivered Twice Daily in Healthy Adult Male Volunteers
Study to Evaluate the Mass Babance and Biotransformation of [14C]SHR6390 in Healthy Adult Male Volunteers
Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR4640 in Chinese Healthy Adult Male Volunteers.
Research Network
Common Treatments
- 14cshr63901
- 14cjaktinib1
- 14clarotinib1
- 14cshr14591
- Beclomethasone Dipropionate1
Active Sponsors
- Jiangsu HengRui Medicine Co., Ltd.3
- Sunshine Lake Pharma Co., Ltd.2
- SOFAR S.p.A.1
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd1
- Tanabe Pharma Corporation1
Top Investigators
The First Affiliated Hospital of Soochow University
Tanabe Pharma Corporation
The First Affiliated Hospital of Soochow University